Replies to post #115772 on Biotech Values

[jbog]

I was surprised yesterday to see a report yesterday that Gilenia is taking very few Tysabri patients. Biogen has had a very nice run as of lately (+ $3 over the week).

Gilenia is still hurting Avonex and Copaxone.